Post by icemandios on Apr 4, 2018 13:25:56 GMT
RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference
Poster presentations will include data from the Company's Phase 2 study with RXI-109 for the reduction of hypertrophic scars, its Phase 2 study with Samcyprone™ for the treatment of cutaneous warts and the consumer testing program with its cosmetic product RXI-231 to improve the appearance of skin pigmentation.
MARLBOROUGH, Mass., April 4, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation, a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will present new data from the Company's Dermatology Franchise at the International Investigative Dermatology (IID) Conference. This conference unites three leading dermatology societies, the European Society of Dermatological Research (ESDR), the Journal of Investigative Dermatology (JSID) and the Society of Investigational Dermatology (SID), into one meeting that takes place every five years. The 2018 IID will hold its seventh meeting this year, where scientists and industry leaders gather from across the world to exchange information and facilitate collaboration. This meeting is being held May 16-19, 2018 at Rosen Shingle Creek Resort in Orlando, Florida.
RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars
RXI-109: sd-rxRNA targeting connective tissue growth factor (CTGF)
Date and Time: Thursday, May 17, 2018, 11:45 am – 1:45 p.m.
Session: Clinical Research, Pathophysiology and Therapeutics
Poster #: 496, Gatlin Ballroom
Samcyprone™ (diphenylcyclopropenone ointment) for the Treatment of Common Warts
Samcyprone: small molecule, proprietary topical formulation of diphenylcyclopropenone (DPCP)
Date and Time: Friday, May 18, 2018, 12:00 pm – 2:00 p.m.
Session: Clinical Research, Pathophysiology and Therapeutics
Poster #: 490, Gatlin Ballroom
Topical Administration of self-delivering RNAi (sd-rxRNA) Compounds for the Reduction of Hyperpigmentation
RXI-231: sd-rxRNA targeting tyrosinase (TYR)
Date and Time: Friday, May 18, 2018, 12:00 pm – 2:00 p.m.
Session: Pigmentation and Melanoma
Poster #: 1257, Gatlin Ballroom
Logo: mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
The posters will be available under the "Investors – Events & Presentations" section of the Company's website, 1 hour following each presentation.
About RXi's Dermatology Franchise
RXi announced in January 2018 that its would exclusively focus on developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi therapeutic platform. As such, it is actively seeking to partner or out-license both its Dermatology and Ophthalmology Franchises.
Each of these Franchises is comprised of a number of preclinical and clinical-stage assets broadly covered by a robust intellectual property estate. To obtain more information about these assets, contact RXi's Director of Business Development, Dr. James Cardia at jcardia@rxipharma.com
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing immuno-oncology therapeutics based on its sd-rxRNA therapeutic platform. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform, including sd-rxRNA compounds, that has the potential to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. For additional information, visit the Company's website,
Poster presentations will include data from the Company's Phase 2 study with RXI-109 for the reduction of hypertrophic scars, its Phase 2 study with Samcyprone™ for the treatment of cutaneous warts and the consumer testing program with its cosmetic product RXI-231 to improve the appearance of skin pigmentation.
MARLBOROUGH, Mass., April 4, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation, a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will present new data from the Company's Dermatology Franchise at the International Investigative Dermatology (IID) Conference. This conference unites three leading dermatology societies, the European Society of Dermatological Research (ESDR), the Journal of Investigative Dermatology (JSID) and the Society of Investigational Dermatology (SID), into one meeting that takes place every five years. The 2018 IID will hold its seventh meeting this year, where scientists and industry leaders gather from across the world to exchange information and facilitate collaboration. This meeting is being held May 16-19, 2018 at Rosen Shingle Creek Resort in Orlando, Florida.
RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars
RXI-109: sd-rxRNA targeting connective tissue growth factor (CTGF)
Date and Time: Thursday, May 17, 2018, 11:45 am – 1:45 p.m.
Session: Clinical Research, Pathophysiology and Therapeutics
Poster #: 496, Gatlin Ballroom
Samcyprone™ (diphenylcyclopropenone ointment) for the Treatment of Common Warts
Samcyprone: small molecule, proprietary topical formulation of diphenylcyclopropenone (DPCP)
Date and Time: Friday, May 18, 2018, 12:00 pm – 2:00 p.m.
Session: Clinical Research, Pathophysiology and Therapeutics
Poster #: 490, Gatlin Ballroom
Topical Administration of self-delivering RNAi (sd-rxRNA) Compounds for the Reduction of Hyperpigmentation
RXI-231: sd-rxRNA targeting tyrosinase (TYR)
Date and Time: Friday, May 18, 2018, 12:00 pm – 2:00 p.m.
Session: Pigmentation and Melanoma
Poster #: 1257, Gatlin Ballroom
Logo: mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
The posters will be available under the "Investors – Events & Presentations" section of the Company's website, 1 hour following each presentation.
About RXi's Dermatology Franchise
RXi announced in January 2018 that its would exclusively focus on developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi therapeutic platform. As such, it is actively seeking to partner or out-license both its Dermatology and Ophthalmology Franchises.
Each of these Franchises is comprised of a number of preclinical and clinical-stage assets broadly covered by a robust intellectual property estate. To obtain more information about these assets, contact RXi's Director of Business Development, Dr. James Cardia at jcardia@rxipharma.com
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing immuno-oncology therapeutics based on its sd-rxRNA therapeutic platform. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform, including sd-rxRNA compounds, that has the potential to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. For additional information, visit the Company's website,